Peritoneal Metastases clinical trials at UCSD
1 research study open to eligible people
open to eligible people ages 18 years and up
This Study is designed to test an investigational product (IP) called LSTA1 (Study drug). LSTA1 is a drug designed to improve the delivery of anti-cancer treatments, such as chemotherapy. Improved delivery of chemotherapy may result in improved anti-cancer effects when given with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastases. Participants will be randomized to receive LSTA1 with HIPEC or HIPEC alone (without LSTA1) at the time of surgery.
La Jolla, California
Our lead scientists for Peritoneal Metastases research studies include Joel Baumgartner.